The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 69,648 |
| Payroll and related costs | 69,995 |
| Lab supplies and outside services | 14,209 |
| Facility costs | 9,934 |
| Professional services | 11,248 |
| Repairs and maintenance | 8,808 |
| Change in fair value of the tempus warrants | 0 |
| Depreciation and amortization | 9,787 |
| Other segment items | 34,092 |
| Interest income | 7,155 |
| Net loss | -81,270 |
| Stock-based compensation expense | 9,429 |
| Depreciation and amortization | 10,046 |
| Noncash operating lease cost | 1,335 |
| Amortization of discount on short-term investments | 3,991 |
| Other | 302 |
| Accounts receivable | 8,063 |
| Inventories and other deferred costs | 204 |
| Prepaid expenses and other assets | 2,224 |
| Accounts payable | 4,550 |
| Accrued and other current liabilities | 2,306 |
| Contract liabilities | -1,538 |
| Operating lease liabilities | -3,820 |
| Other long-term liabilities | -1,200 |
| Net cash used in operating activities | -74,946 |
| Purchases of available-for-sale debt securities | 210,174 |
| Proceeds from maturities of available-for-sale debt securities | 192,110 |
| Purchases of property and equipment | 4,504 |
| Net cash used in investing activities | -22,568 |
| Proceeds from sales of common stock under atm facility, net of commissions | 126,797 |
| Payment of costs related to tempus and merck investment agreements | 189 |
| Proceeds from loans | 2,587 |
| Repayments of loans | 2,002 |
| Proceeds from issuance of common stock under equity incentive plans | 3,145 |
| Net cash provided by financing activities | 130,338 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 6 |
| Net change in cash, cash equivalents and restricted cash | 32,830 |
| Cash, cash equivalents and restricted cash, beginning of period | 93,205 |
| Cash, cash equivalents and restricted cash, end of period | 126,035 |
Personalis, Inc. (PSNL)
Personalis, Inc. (PSNL)